Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven®) and Fibrinogen (Haemocomplettan® P)

BACKGROUND: Recombinant activated factor VII (rFVIIa) is increasingly used for treating refractory bleeding after cardiac surgery. However, hemostasis also depends on coagulation factors, including fibrinogen, which stabilizes platelet plugs at sites of vascular injury. We compared the hemostatic effects of rFVIIa, fibrinogen, or their combination. METHODS: Blood samples were obtained from 12 volunteers and from 7 patients after cardiopulmonary bypass (CPB). The in vitro effects of rFVIIa (1.5 &mgr;g/mL), fibrinogen (100 mg/dL), and the combination were evaluated under simulated coagulopathy in volunteer plasma using heparin (0.1 U/mL) or tissue plasminogen activator (0.1 &mgr;g/mL). Hemostatic interventions were compared using thromboelastometry, which measures clotting time (CT, s), angle of thrombus formation, and maximal clot firmness (MCF, mm). The Thrombinoscope™ was used to quantitate thrombin generation after addition of fibrinogen and/or rFVIIa. RESULTS: In heparinized volunteer plasma, rFVIIa shortened CT (1st and 3rd quartiles) from 663 (522–736) to 435 (397–531) s, but it did not affect MCF. Fibrinogen increased MCF from 26.0 (24.4–26.7) to 30.5 (26.3–31.5) mm without affecting CT. The combination of rFVIIa and fibrinogen in heparinized samples was most effective in improving CT to 359 (324–522) s and MCF to 29 (27.8–31.0) mm. In tissue plasminogen activator-treated volunteer plasma, fibrinolysis increased by more than 45% by the addition of rFVIIa. After CPB, both CT and MCF were most improved with coadministration of rFVIIa and fibrinogen. Thrombinoscope evaluation demonstrated that rFVIIa decreased the lag time and increased peak thrombin generation, whereas fibrinogen had no effect. CONCLUSION: The onset of fibrin formation and thrombin generation were shortened after rFVIIa addition, but fibrin clot strength was only increased after fibrinogen supplementation. In vitro clot formation was most improved by using both rFVIIa and fibrinogen in whole blood after CPB.

[1]  O. Gajic,et al.  Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. , 2007, Chest.

[2]  Kenichi A. Tanaka,et al.  Coagulopathy After Cardiopulmonary Bypass in Jehovah’s Witness Patients: Management of Two Cases Using Fractionated Components and Factor VIIa , 2007, Anesthesia and analgesia.

[3]  Brad L Steenwyk,et al.  Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  J. Ingerslev,et al.  Coagulopathy induced by colloid plasma expanders – search for an efficacious haemostatic intervention , 2006, Acta anaesthesiologica Scandinavica.

[5]  Alisa S Wolberg,et al.  High dose factor VIIa improves clot structure and stability in a model of haemophilia B , 2005, British journal of haematology.

[6]  E. Beltrami,et al.  Positive feedbacks of coagulation: their role in threshold regulation. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[7]  T. Haas,et al.  Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. , 2005, British journal of anaesthesia.

[8]  P. D. de Groot,et al.  Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count , 2005, Journal of thrombosis and haemostasis : JTH.

[9]  S. Body,et al.  Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes , 2004, Transfusion.

[10]  M. Mann,et al.  Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. , 2004, Anesthesia and analgesia.

[11]  H. Heijnen,et al.  Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation , 2004 .

[12]  Alisa S Wolberg,et al.  The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. , 2003, The Journal of trauma.

[13]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[14]  Kenichi A. Tanaka,et al.  Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). , 2003, Anesthesiology.

[15]  A. Yoshioka,et al.  The In Vitro Analysis of the Coagulation Mechanism of Activated Factor VII Using Thrombelastogram , 2002, Thrombosis and Haemostasis.

[16]  P. D. de Groot,et al.  Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation , 2002, Hepatology.

[17]  D. Monroe,et al.  A Cell-based Model of Hemostasis , 2001, Thrombosis and Haemostasis.

[18]  G. Nuttall,et al.  Efficacy of a Simple Intraoperative Transfusion Algorithm for Nonerythrocyte Component Utilization after Cardiopulmonary Bypass , 2001, Anesthesiology.

[19]  B. Bouma,et al.  Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[20]  M. Al Douri,et al.  Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  S. Kleinman,et al.  A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care , 1999 .

[22]  M. DePerio,et al.  Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. , 1999, Anesthesia and analgesia.

[23]  N. Nagai,et al.  Human Thrombin and Calcium Bound Factor Xa Significantly Shorten tPA-Induced Fibrin Clot Lysis Time via Neutralization of Plasminogen Activator Inhibitor Type 1 Activity , 1998, Thrombosis and Haemostasis.

[24]  E. Spitznagel,et al.  More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT , 1996, Thrombosis and Haemostasis.

[25]  Jordi Félez,et al.  Competition between plasminogen and tissue plasminogen activator for cellular binding sites. , 1993, Blood.

[26]  S. Slack,et al.  The Effects of Flow on Blood Coagulation and Thrombosis , 1993, Thrombosis and Haemostasis.

[27]  R. Hillman,et al.  Platelet activation and aggregation during cardiopulmonary bypass. , 1991, Anesthesiology.

[28]  E. Seifried,et al.  Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. , 1989, The American journal of cardiology.

[29]  P. D. de Groot,et al.  Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. , 2004, Blood.

[30]  A.,et al.  Bleeding Complications Associated With Cardiopulmonary Bypass , 2003 .

[31]  J. van der Maaten,et al.  An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. , 2001, Anesthesia and analgesia.

[32]  T. W. Love,et al.  Pharmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant, TNK-tPA, in Patients with Acute Myocardial Infarction , 1998, Thrombosis and Haemostasis.

[33]  W. Chandler.  The effects of cardiopulmonary bypass on fibrin formation and lysis: is a normal fibrinolytic response essential? , 1996, Journal of cardiovascular pharmacology.